Moderna Stock Surges As It Swings For Pfizer, GSK With New RSV … – Investor's Business Daily

BREAKING: Futures Tilt Higher, Yields Fall As Bank Of Japan Stays Course

Moderna (MRNA) stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective against respiratory symptoms in older adults.
The company tested its vaccine in people age 60 and older. It was 83.7% effective against the symptoms of respiratory syncytial virus, or RSV. The virus causes cold-like symptoms. It can be deadly in infants who have virtually nonexistent immune systems and older adults who have weakened immunity.
“Today’s results represent an important step forward in preventing lower respiratory disease due to RSV in adults 60 years of age and older,” Moderna Chief Executive Stephane Bancel said in a written statement. “These data are encouraging and represent the second demonstration of positive Phase 3 (study) results from our (messenger RNA) infectious disease platform.”
In after-hours action on the stock market today, Moderna stock surged 5.3% near 201.
The news adds fodder to a battle already brewing between Pfizer (PFE) and GSK (GSK), both of which are approaching Food and Drug Administration review dates for their shots in older adults. Bavarian Nordic, which doesn’t trade in the U.S., is also working on an RSV vaccine.
Moderna’s study involved 37,000 adults age 60 or older in 22 countries, including the U.S. The company reported an interim analysis, examining the number of participants to develop two or more symptoms of RSV. Of the 64 people to develop symptoms, 55 received the placebo. Nine were vaccine recipients.
Another measure looked at participants to develop three or more symptoms of RSV. Moderna said there were 20 people in the study to hit that mark, including 17 placebo recipients and three vaccinated people. That put the effectiveness at 82.4%.
Moderna stock has trended slightly higher this month with a strong Relative Strength Rating of 90 out of a best-possible 99, according to IBD Digital. This puts shares in the leading 10% of all stocks in terms of 12-month performance.
By comparison, GSK has said its RSV vaccine was almost 83% effective overall and more than 94% protective against severe RSV in adults age 60 and older with underlying health problems. Pfizer’s shot was close to 67% protective overall and about 86% effective against severe disease.
Bullishly for Moderna stock, an independent team of data monitors reviewed Moderna’s test results and said there have been no safety concerns. The study is ongoing.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Novocure Has Fallen More Than 22% Over Seven Days — Why It Fell From Grace
Pfizer Stock Dives As Analyst Calls For ‘Covid Reset’ And Downgrades Shares
Options Trading: How To Start Using Options, How To Manage Risk
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
MarketSmith: Research, Charts, Data And Coaching All In One Place
1/17/2023 Futures rose and yields fell as the Bank of Japan stayed dovish. The market rally paused while Tesla stock jumped….
1/17/2023 Futures rose and yields fell as the Bank of Japan…
Strong performances by S&P 500 stocks Caterpillar and Freeport McMoRan reveal several drivers for the industrial economy. (©Vadim Ratnikov/Shutterstock)
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2023 Investor’s Business Daily, LLC. All rights reserved

source